Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) Forecasted to Earn FY2026 Earnings of $0.06 Per Share

Lineage Cell Therapeutics, Inc. (NYSEAMERICAN:LCTX) – Equities researchers at HC Wainwright lifted their FY2026 earnings per share estimates for shares of Lineage Cell Therapeutics in a research note issued to investors on Friday, November 10th. HC Wainwright analyst J. Pantginis now anticipates that the company will post earnings per share of $0.06 for the year, up from their previous estimate of $0.03. HC Wainwright currently has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Lineage Cell Therapeutics’ current full-year earnings is ($0.15) per share.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last issued its earnings results on Thursday, August 10th. The company reported ($0.03) earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.01. The business had revenue of $3.23 million for the quarter, compared to analyst estimates of $2.65 million. Lineage Cell Therapeutics had a negative return on equity of 32.61% and a negative net margin of 262.94%.

Separately, Cantor Fitzgerald reiterated an “overweight” rating and issued a $6.00 price target on shares of Lineage Cell Therapeutics in a report on Tuesday, July 25th.

Lineage Cell Therapeutics Price Performance

Shares of NYSEAMERICAN LCTX opened at $1.04 on Monday. Lineage Cell Therapeutics has a 12-month low of $1.00 and a 12-month high of $1.58. The firm has a market capitalization of $181.99 million, a P/E ratio of -8.00 and a beta of 1.65.

Institutional Trading of Lineage Cell Therapeutics

Large investors have recently modified their holdings of the business. Fort Sheridan Advisors LLC grew its stake in shares of Lineage Cell Therapeutics by 13.5% during the second quarter. Fort Sheridan Advisors LLC now owns 83,931 shares of the company’s stock valued at $118,000 after acquiring an additional 10,000 shares in the last quarter. Wealth Architects LLC bought a new position in shares of Lineage Cell Therapeutics during the first quarter worth about $25,000. Defender Capital LLC. lifted its position in shares of Lineage Cell Therapeutics by 1.5% during the third quarter. Defender Capital LLC. now owns 5,184,510 shares of the company’s stock worth $6,118,000 after purchasing an additional 74,800 shares during the last quarter. Barclays PLC lifted its position in shares of Lineage Cell Therapeutics by 87.3% during the second quarter. Barclays PLC now owns 25,905 shares of the company’s stock worth $36,000 after purchasing an additional 12,075 shares during the last quarter. Finally, Raffles Associates LP lifted its holdings in Lineage Cell Therapeutics by 4.0% in the second quarter. Raffles Associates LP now owns 1,597,739 shares of the company’s stock worth $2,253,000 after acquiring an additional 60,793 shares during the last quarter. 43.42% of the stock is currently owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.